In summary, our study has demonstrated that FGFR1 amplification in ER + breast cancer cells activate a collateral JAK-STAT pathway and leads to p21 upregulation, which inhibits the proliferation of cancer cells and enhances their stemness properties with FGF2 simulation. Here, FGF2 is linked to breast cancer.